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Tablet formulationAbstract An HPTLC method for analysis of Exemestane in bulk and pharmaceutical formulation
has been established and validated. The analyte was separated on aluminium plates precoatedwith sil-
ica gel 60 F254. The mobile phase was chloroform:methanol 9.2:0.8 (v/v). Quantiﬁcation was done by
densitometric scanning at 247 nm.Response was a linear function of Exemestane concentration in the
range of 100–500 lg mL1. The limit of detection and quantiﬁcation for Exemestane were 5.8
and 17.58 lg mL1, respectively. Average recovery of Exemestane was 100.1, which shows that the
method was free from interference from excipients present in the formulation. The established
method enabled accurate, precise, and rapid analysis of Exemestane in bulk as well as pharmaceutical
formulation.
ª 2010 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Exemestane is an orally active irreversible steroidal aromatase
inhibitor used for the therapy of metastatic postmenopausal
breast cancer, with estrogen-dependent pathological condi-
tions (Johannessen et al., 1997; Evans et al., 1992; Geisler
et al., 1998). The chemical name of Exemestane is 10,13-di-
methyl-6-methylidene-7,8,9,10,11,12,13,14,15,16-decahydrocy-
clopenta[a] phenanthrene-3,17-dione (Fig. 1).Literature survey reveals that several methods were re-
ported for the estimation of Exemestane. The determinations
of Exemestane in biological samples using HPLC (Persiani
et al., 1996), mass (Allievi et al., 1995) and liquid chromatog-
raphy–mass spectrometry (Cenacchi et al., 2000) is also re-
ported. To the best of our knowledge no ofﬁcial report for
the determination of Exemestane in bulk material and tablets
has ever been published by densitometry. Thus, we thought
that it would be of particular interest to develop and validate
an HPTLC method for the quality control of Exemestane in
the pharmaceutical preparations that would also reduce the
sample throughput. The proposed method can be applicable
for routine analysis and content uniformity test of Exemestane
in tablets and complies well with the validation requirements in
the pharmaceutical industry. The developed method is vali-






Figure 1 The structure of Exemestane.
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2.1. Materials
The tablet formulation was procured from local pharmacy
(Sun Pharmaceuticals Ltd., India). Pure Exemestane were ob-
tained from (Cipla Ltd., Mumbai, India). All chemicals were
of analytical grade. All dilutions were performed in standard
volumetric ﬂasks.
2.2. Instrumentation
HPTLC system––Desaga HPTLC system with densitometer
CD 60 and auto sampler model AS 30 (Desaga, Wiesloch, Ger-
many). Twin tough developing chamber (Desaga)
200 · 100 mm, Mettler analytical balance (Mettler-Toledo,
Columbus, Ohio), and model AE 240 (accuracy ±0.01 mg)
Ultrasound cleaning bath.
2.3. Stock and working standard solution
Exemestane (25 mg) was accurately weighed into a 25 mL volu-
metric ﬂask, and dissolved in a minimum volume of water, and
diluted to required volume with water to furnish a solution of
concentration 1000 lg mL1. This was used as stock solution.
Calibration standards were prepared over the concentration
range 100–500 lg mL1 for Exemestane by appropriate dilu-
tions of the above mentioned standard stock solution in
10 mL volumetric ﬂask with methanol.
2.4. Sample preparation
Twenty tablets were weighed and the average weight was
calculated. The tablets were then powdered and amountFigure 2 HPTLC densitogramequivalent to 25 mg of pure Exemestane tablet was dissolved
in a minimum volume of methanol. This was then ﬁltered
through Whatman ﬁlter paper number 41 and ﬁltrate was
collected in a 10 mL volumetric ﬂask and diluted to volume
with methanol to get stock solution of concentration of
100 lg mL1. Similarly various required strength dilutions of
the tablet sample solution is done and analyzed by proposed
method and concentration was calculated by using the calibra-
tion curve.
2.5. Calibration curve
Separate stock standard solutions of Exemestane were used for
the preparation of calibration standard solutions. All calibra-
tion standards were prepared freshly every day and found to
be stable during the analysis time. The plate was developed,
dried, and scanned as described above. After densitometric
scanning the peak area was recorded for each concentration
and a calibration plot was obtained by plotting average peak
area against concentration of Exemestane (ng spot1). The
slope and correlation coefﬁcient were also determined.
2.6. Standard chromatographic HPTLC conditions
Analysis was performed on silica gel 60 F254 plates of size
200 · 100 mm. Different volumes of the samples (experimental
sample solution and reference standard solution) were applied
on the plate separately or together with standard drug solu-
tion. Samples (5.00 lL) were applied as 5 mm bands by means
of Desaga auto sampler automatic applicator (model AS30)
equipped with 10 lL syringe at different positions (lane) on
the HPTLC plate under N2 gas stream. Application parame-
ters were the length of the band is 5 mm, distance between
bands was 10 mm, the application position along Y axis was
15 mm, and the start position along X axis was 15.0 mm. Each
spot was given by a 1 lL/cycle with application rate of 0.1 lL/
s. Linear ascending development is carried out in twin trough
glass chamber (200 · 100 mm) covered with stainless steel lid.
The optimized chamber saturation time for mobile phase
was 25 min at room temperature and the plates were developed
up to 80 mm from the bottom of the plate using the solvent
systems chloroform:methanol 9.2:0.8 (v/v) as a mobile phase.
The average development time was 20 min. After developmentobtained from Exemestane.
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scanning at k= 247 nm was performed. After densitometric
scanning, chromatograms were evaluated via peak area.
Scanned peak areas were recorded for each sample at each
concentration level. In assay experiment six samples were
weighed separately and analyzed. For each sample, each con-
centration was applied six times to the plate at each concentra-
tion level. These developed plates are scanned by performing
six replicate measurements of peak areas of the six bands of
same concentration. The average peak areas, variations in
peak area obtained were expressed as a coefﬁcient of variation
(% CV) and concentration of the drug present were automat-
ically calculated by comparing the peak area values of the sam-
ple with that of the reference standard. The plot was obtained
by plotting average peak area at each concentration against the
corresponding band concentrations of Exemestane
(ng spot1). From the constructed calibration curve slope,
correlation coefﬁcient was calculated. The % CV of six inde-
pendent assays values is calculated. From amount of drug
present in sample, % assay of Exemestane was calculated.
2.7. Validation
The proposed method was validated according to the ICH
guidelines by carrying out analysis of six replicate samples of
the tablets. The method was validated for accuracy, precision,
robustness, linearity and range, selectivity, limit of detection,
limit of quantiﬁcation and robustness.
2.7.1. Linearity
The linearity of the method was evaluated by analysis of the
ﬁve standard solutions at ﬁve different concentrations from
100 to 500 lg mL1, prepared from the stock solution. At each
concentration level these solutions (1 lL) were applied to
plates and then these plates were developed, scanned as de-
scribed above. Peak area was recorded for Exemestane. Areas
under the curve and drug concentration were subjected to
regression analysis to calculate the regression equations and
correlation coefﬁcients.
2.7.2. Limit of detection and limit of quantiﬁcation
The limits of detection (LOD) and quantiﬁcation (LOQ) were
estimated experimentally and mathematically using formulae:
LOD ¼ 3 : 3 ðstandard deviation of intercept=
slope of the calibration plotÞ
LOQ ¼ 10 ðstandard deviation of intercept=
slope of the calibration plotÞ
LOD and LOQ values were experimentally veriﬁed by diluting
known concentrations of a standard solution of Exemestane
until the average responses were approximately 3/10 times
the standard deviations of the responses for the six replicate
determinations. The LOD and LOQ were determined from
the graph of the lowest part of the calibration plot and found
to be 5.8 and 17.58 ng spot1.
2.7.3. Precision
Repeatability studies were performed by the analysis of three
different concentrations (200, 300 and 500 ng per band).
Repeatability was determined by running minimum of sixanalyses per sample and evaluating the coefﬁcient of
variation (CV [%]) for each sample. Each concentration
was applied six times to the HPTLC plate on the same
day. The precision of the method as repeatability intra-day
assay precision [CV %] was assessed by performing six inde-
pendent analyses of sample and qualiﬁed reference standards
together at 100% of the test concentration. Inter-day preci-
sion was determined by repeating the analysis of the same
Exemestane tablet by repeating studies by three different ana-
lysts on three different days over a period of 1 week also ex-
pressed in terms of [%] CV.
2.7.4. Repeatability and reproducibility
Repeatability can be deﬁned as the precision of the procedure
when repeated by same analyst under the same operating con-
ditions (same reagents, equipments, settings and laboratory)
over a short interval of time. Repeatability was further con-
ﬁrmed by determination of CV [%] for standard addition at
three concentrations levels. In assay experiment six samples
were weighed separately analyzed and the results of indepen-
dent assay of the 200, 300 and 500 ng per band given in table.
Reproducibility means the precision of the procedure when it
is carried out under different conditions.
2.7.5. Accuracy by recovery
Accuracy of the method was ascertained by performing recov-
ery studies by the standard addition method at different levels,
i.e., 0%, 80%, 100% and 120% by adding pure standard drug
of Exemestane to previously analyzed tablet powder sample
and mixtures were reanalyzed by the proposed method. From
the amount of drug found percentage recovery was calculated.
The experiment was conducted in triplicate.
2.7.6. Selectivity and speciﬁcity
The selectivity of an analytical method is its ability to measure
accurately and speciﬁcally the analyte of interest in the pres-
ence of components that may be expected to be present in
the sample matrix for example impurities, degradation prod-
ucts, and matrix components. A UV spectrum of Exemestane
was initially obtained by scanning a developed plate in screen-
ing mode to select the detection wavelength. For each sample,
UV spectra taken at the edges and maxima of the Exemestane
peaks were compared automatically to verify peak purity.
Speciﬁcity of the method was ascertained by analyzing stan-
dard drug and samples of equivalent concentration (25 mg).
The speciﬁcity of the method was established by analyzing
marketed tablet as an experimental sample together with the
reference standard using proposed method. The spot for Exe-
mestane in sample was conﬁrmed by comparing the RF and
spectra of the spot in samples with those of standard. The peak
purity of sample was judged by comparing the spectra at peak
start, peak apex and peak end positions of the spot.
2.7.7. Robustness
The robustness of an analyticalmethod is ameasure of its capac-
ity to remain unaffected by small but deliberate variation in
method parameters and provides an indication of its reliability
during normal usage by introducing small changes in the mobile
phase composition; the effects on the results were examined.
Mobile phases having diverse composition of chloroform:meth-
anol was tried at two different concentration levels of 100 and
200 ng spot1 and % CV of peak area was calculated.
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The ruggedness of an analytical method is the degree of repro-
ducibility of test results obtained by the analysis of the same
samples under a variety of normal test conditions such as dif-
ferent laboratories, different analysts, using operational and
environmental conditions that may differ but are still within
the speciﬁed parameters of the assay. The ruggedness of the
method was assessed by analysis of 100 ng Exemestane by
two different analysts under the same experimental conditions.
2.8. Analysis of marketed formulation
In assay experiment ﬁve samples weighed separately were ana-
lyzed. The standard solution of Exemestane of strength
(100 lg mL1) and the experimental solution (extracted from
marketed tablet) of strength (100 lg mL1) were prepared by
the above described procedure. For tablet assay linearity study
the solutions were prepared containing 100–500 lg mL1. The
standard solution of Exemestane of strength (100 lg mL1)
and the experimental solution of strength (100 lg mL1) was
applied on HPTLC plate together with reference standard by
using the proposed method. Then it was developed andTable 1 Summary of calibration data.
Sr. No. Parameters Mean value
1 Linear range 100–500
2 Correlation coeﬃcient (r) 0.9944
3 Slope of regression 26.12
4 Limit of detection 5.8
5 Limit of quantiﬁcation 17.57
Each linear range is a mean of six observations.
Table 2 Results from the study of the recovery of Exemestane.
Recovery level Initial amount Exemestane added Total amo
0 500 0 500
80 500 400 900
100 500 500 1000




Each value is a mean of six observations.
Table 3 Summary of intra-day and inter-day method precision.
Amount [ng spot1] Intra-day precision by peak area





Each value is a mean of six observations.scanned under the optimized conditions by the proposed
method.
3. Results and discussion
HPTLC of Exemestane using the conditions described above
enabled good separation of Exemestane (RF 0.60). Results
from calibration showed there was excellent correlation be-
tween area under curve and drug concentration in the range
of 100–500 lg mL1. The regression coefﬁcient was 0.9969
for Exemestane. The limit of detection and quantiﬁcation
was found to be 1.068–3.237 lg mL1 (Table 1).
Average recovery of Exemestane from the formulation was
100.097%, which shows the method is accurate and free from
interference of excipients present in the formulation (Table 2).
Instrument precision, intra-day and inter-day precision
were measured to evaluate the precision of the method (Tables
3 and 4). The low relative standard deviations obtained
(<2%) indicate the method is highly precise. The repeatability
of sample application and measurement of peak area were ex-
pressed in terms of coefﬁcient of variation and were found to
be very low (0.992346939 and 1.020055828 for Exemestane)
which, in turn, insured reproducible performance of the
instrument.
The results of the speciﬁcity studies showed that Exemes-
tane is stable when exposed to different stress conditions.
Any degradation byproducts that may be present in Exemes-
tane were not observed in chromatograms studied. Signiﬁcant
no variations of assay values were observed. Robustness was
studied during method development by determining effects
of small variation of mobile phase composition (±2%), cham-
ber saturation period, development distance, and scanning
time. No signiﬁcant change in RF or response was observed,
indicating the method was robust. Overall method repeatabil-
ity was determined by calculating the coefﬁcient of variation,unt Exemestane found % Recovery SD % RSD
496.5 99.29 0.056 0.0572
895 99.44 1.680 1.69
998.5 99.85 1.532 1.58




Inter-day precision by peak area
CV [%] Average peak area SD of peak area CV [%]
1.68 980.56 16.87 1.72
1.88 1287.98 22.15 1.72
1.53 1953.12 29.1 1.49
1.6967 1.6433
Table 5 Summary of method validation parameters.
Parameter Exemestane
Linearity range (ng spot1) 100–500
Correlation coeﬃcient 0.9944
Limit of detection (ng spot1) 5.8
Limit of quantitation (ng spot1) 17.57
Recovery (mean ± S.D.) 100.0975 ± 1.67
Precision (CV)
Repeatability of application (n= 6) 0.99
Repeatability of measurement (n= 6) 1.02
Intra-day (n= 6) 1.6967
Inter-day (n= 3) 1.6433
Robustness Robust















Mean area 194.5 989.7091667
SD 4.086563348 10.51022859
CV 0.992346939 1.020055828
508 M.B. Mane et al.CV [%], for all the validation experiments and sample analy-
ses; all values were within 5%. The analysis of the Exemestane
in tablet formulation was also carried out. The % assay was
found to be 103.12.The summary of all the validation parameters is given in
Table 5.4. Conclusion
The low % CV value obtained indicates that the suitability of
this method for routine analysis and quantitative determina-
tion of the Exemestane in the ﬁxed dosage form by High-per-
formance thin-layer chromatographic. The statistical analysis
of data obtained proves that the method is reproducible and
selective, was found to be simple, accurate and precise. The
method can, therefore, be used for routine quality-control
analysis and quantitative determination of Exemestane in
formulations.Acknowledgement
The authors are thankful to the Head of the Department of
Chemical Technology, Dr. Babasaheb Ambedkar Marathw-
ada University, Aurangabad 431 004, MS, India for providing
the laboratory facility.References
Allievi, C., Zugnoni, P., Strolin Benedetti, M., Dostert, P., 1995. J.
Mass Spectrom. 30, 693.
Cenacchi, V., Baratte, S., Cicioni, P., Frigerio, E., Long, J., James, C.,
2000. J. Pharm. Biomed. Anal. 22, 451.
Evans, T.R., Di Salle, E., Ornati, G., Lassus, M., Benedetti, M.S.,
Painezzola, E., Coombes, R.C., 1992. Cancer Res. 52, 5933.
Geisler, J., King, N., Anker, G., Ornati, G., Di Salle, E., Lonning,
P.E., Dowsett, M., 1998. Clin. Cancer Res. 4, 2089.
Johannessen, D.C., Engan, T., Di Salle, E., Zurlo, M.G., Paolini, J.,
Ornati, G., Piscitelli, G., Kvinnsland, S., Lonning, P.E., 1997. Clin.
Cancer Res. 3, 1101.
Persiani, S., Broutin, F., Cicioni, P., Stefanini, P., Strolin Benedetti,
M., 1996. Eur. J. Pharm. Sci. 4, 331.
